-
公开(公告)号：US12076381B2
公开(公告)日：2024-09-03
申请号：US17576185
申请日：2022-01-14
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
CPC分类号： A61K39/0011 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/5748 , G01N33/6848 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2310/16 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11826409B2
公开(公告)日：2023-11-28
申请号：US17320938
申请日：2021-05-14
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68
CPC分类号： A61K39/0011 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/5748 , G01N33/6848 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2310/16 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10449238B2
公开(公告)日：2019-10-22
申请号：US16385221
申请日：2019-04-16
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K38/00 , A61K39/00 , G01N33/574 , C12Q1/6886 , C12N5/0783 , C07K16/30 , C07K14/47 , C12N15/115 , C07K14/725 , G01N33/68
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
4.发明授权公开(公告)号：US11988669B2
公开(公告)日：2024-05-21
申请号：US16685765
申请日：2019-11-15
发明人： Toni Weinschenk , Julia Leibold
IPC分类号： G01N33/68 , A61K39/00 , G01N33/569 , C07K14/74
CPC分类号： G01N33/6848 , G01N33/56977 , G01N33/6842 , G01N33/6878 , G01N2333/70539 , G01N2458/15 , G01N2496/00 , G01N2560/00 , G01N2570/00
摘要： The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and/or autoimmune diseases.
-
公开(公告)号：US11071773B2
公开(公告)日：2021-07-27
申请号：US17150617
申请日：2021-01-15
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Claudia Wagner , Julia Leibold , Colette Song
IPC分类号： A61K39/00 , G16B20/20 , A61K35/17 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61P35/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10799569B2
公开(公告)日：2020-10-13
申请号：US16552873
申请日：2019-08-27
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
7.发明授权公开(公告)号：US10545154B2
公开(公告)日：2020-01-28
申请号：US14969423
申请日：2015-12-15
发明人： Toni Weinschenk , Julia Leibold
摘要： The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and/or autoimmune diseases.
-
公开(公告)号：US10238727B2
公开(公告)日：2019-03-26
申请号：US16153294
申请日：2018-10-05
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Müller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/395 , A61K39/00 , G01N33/68 , C07K14/47 , C07K14/725 , C12N15/115 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K38/00
摘要： A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
-
公开(公告)号：US12097249B2
公开(公告)日：2024-09-24
申请号：US17581049
申请日：2022-01-21
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
CPC分类号： A61K39/0011 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/5748 , G01N33/6848 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2310/16 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
10.发明授权公开(公告)号：US11058754B2
公开(公告)日：2021-07-13
申请号：US16915465
申请日：2020-06-29
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.04 秒)
